Effect of PTH(1-34) Treatment on Fracture Healing in Vivo
NCT ID: NCT00741182
Last Updated: 2015-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2008-10-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?
NCT01105832
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
NCT00172081
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
NCT00479037
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
NCT01224717
PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial
NCT02972424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Femur PTH(1-34)
24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
rhPTH(1-34)
Injection of 20 micrograms per day in eight weeks
Femur Control
24 participants with trochanteric fractures will be assigned to "no treatment"
No interventions assigned to this group
Humerus PTH(1-34)
24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
rhPTH(1-34)
Injection of 20 micrograms per day in eight weeks
Humerus Control
24 participants with collum chirurgicum fracture will be assigned to "no treatment".
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rhPTH(1-34)
Injection of 20 micrograms per day in eight weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Postmenopause
Exclusion Criteria
* Diseases known to affect calcium homeostasis
* Dementia
* Hypersensitivity to drug or other components of medication
* pre-existing hypercalcemia
* Decreased kidney function
* Increased alkaline phosphatase
* Prior external radiation therapy or brachytherapy of the skeleton
* Skeletal malignancies or bone metastases
* Alcohol and/or drug abuse
* Systemic treatment with corticosteroids within the last four weeks
* Non-cooperating patients
* Patients who do not speak and understand the danish language
50 Years
85 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Danish Medical Research Council
OTHER
Glostrup University Hospital, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Glostrup University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Schwarz, MD, DMSci
Role: PRINCIPAL_INVESTIGATOR
Glostrup University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Center for Ageing and Osteoporosis, Glostrup University Hospital
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT 2008-000094-37
Identifier Type: -
Identifier Source: secondary_id
FAO_06_011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.